Shanti Amé

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel et al. · Blood · 2010 · 383 citations · Full text

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Delphine Réa, Shanti Amé, Marc Berger et al. · Cancer · 2018 · 72 citations · Full text

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

Jean‐Claude Chomel, Marie Laure Bonnet, Nathalie Sorel et al. · Oncotarget · 2016 · 62 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Tumor Biology +18

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study

Franck E. Nicolini, Gabriel Étienne, Viviane Dubruille et al. · The Lancet Haematology · 2015 · 53 citations

Hematological Malignancy, Open-label Phase 2, Medicine +8

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

Charikleia Kelaïdi, Odile Beyne‐Rauzy, Thorsten Braun et al. · Annals of Hematology · 2013 · 48 citations

Darbepoetin Alfa, Hematology, High Response Rate +4